[go: up one dir, main page]

WO2008017000A3 - Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy - Google Patents

Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy Download PDF

Info

Publication number
WO2008017000A3
WO2008017000A3 PCT/US2007/075008 US2007075008W WO2008017000A3 WO 2008017000 A3 WO2008017000 A3 WO 2008017000A3 US 2007075008 W US2007075008 W US 2007075008W WO 2008017000 A3 WO2008017000 A3 WO 2008017000A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemotherapy
treatment
methods
pharmaceutical preparations
contributing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/075008
Other languages
French (fr)
Other versions
WO2008017000A2 (en
WO2008017000A8 (en
Inventor
Guru Reddy
Doria Mirejovsky
Luigi Lenaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spectrum Pharmaceuticals Inc
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2009523049A priority Critical patent/JP2009545619A/en
Priority to MX2009001116A priority patent/MX2009001116A/en
Priority to BRPI0715504-2A priority patent/BRPI0715504A2/en
Priority to CA002659477A priority patent/CA2659477A1/en
Priority to EP07840646A priority patent/EP2046335A2/en
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of WO2008017000A2 publication Critical patent/WO2008017000A2/en
Publication of WO2008017000A3 publication Critical patent/WO2008017000A3/en
Priority to NO20090279A priority patent/NO20090279L/en
Priority to IL196824A priority patent/IL196824A0/en
Anticipated expiration legal-status Critical
Publication of WO2008017000A8 publication Critical patent/WO2008017000A8/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods and pharmaceutical preparations for using a leteprinim suspension to contribute to the treatment of chemotherapy-induced neuropathy.
PCT/US2007/075008 2006-08-01 2007-08-01 Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy Ceased WO2008017000A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2009523049A JP2009545619A (en) 2006-08-01 2007-08-01 Methods and pharmaceutical formulations for contributing to the treatment of chemotherapy-induced neuropathy
MX2009001116A MX2009001116A (en) 2006-08-01 2007-08-01 Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy.
BRPI0715504-2A BRPI0715504A2 (en) 2006-08-01 2007-08-01 PHARMACEUTICAL METHODS AND PREPARATIONS TO CONTRIBUTE TO THE TREATMENT OF CHEMOTHERAPY-INDUCED NEUROPATHY.
CA002659477A CA2659477A1 (en) 2006-08-01 2007-08-01 Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy
EP07840646A EP2046335A2 (en) 2006-08-01 2007-08-01 Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy
NO20090279A NO20090279L (en) 2006-08-01 2009-01-19 Methods and Pharmaceutical Preparations to Assist in the Treatment of Chemotherapy-Induced Neuropathy
IL196824A IL196824A0 (en) 2006-08-01 2009-02-01 Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82108206P 2006-08-01 2006-08-01
US60/821,082 2006-08-01

Publications (3)

Publication Number Publication Date
WO2008017000A2 WO2008017000A2 (en) 2008-02-07
WO2008017000A3 true WO2008017000A3 (en) 2008-03-20
WO2008017000A8 WO2008017000A8 (en) 2009-04-30

Family

ID=38744846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/075008 Ceased WO2008017000A2 (en) 2006-08-01 2007-08-01 Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy

Country Status (12)

Country Link
EP (1) EP2046335A2 (en)
JP (1) JP2009545619A (en)
KR (1) KR20090047501A (en)
CN (1) CN101657199A (en)
BR (1) BRPI0715504A2 (en)
CA (1) CA2659477A1 (en)
IL (1) IL196824A0 (en)
MX (1) MX2009001116A (en)
NO (1) NO20090279L (en)
RU (1) RU2009107123A (en)
WO (1) WO2008017000A2 (en)
ZA (1) ZA200900728B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055506A1 (en) * 2000-07-07 2002-05-09 Jack Diamond Methods for treatment of disease-induced peripheral neuropathy and related conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055506A1 (en) * 2000-07-07 2002-05-09 Jack Diamond Methods for treatment of disease-induced peripheral neuropathy and related conditions
US20020061899A1 (en) * 2000-07-07 2002-05-23 Jack Diamond Methods for treatment of drug-induced peripheral neuropathy and related conditions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAVALETTI G ET AL: "Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, no. 14, September 2002 (2002-09-01), pages 1832 - 1837, XP004377449, ISSN: 0959-8049 *
HOLMES MICHAEL ET AL: "Neotrofin, a novel purine that induces NGF-dependent nociceptive nerve sprouting but not hyperalgesia in adult rat skin.", MOLECULAR AND CELLULAR NEUROSCIENCE, vol. 24, no. 3, November 2003 (2003-11-01), pages 568 - 580, XP002461145, ISSN: 1044-7431 *
REDDY ET AL: "221 POSTER Leteprinim attenuates cisplatin-induced neuropathy", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 4, no. 12, November 2006 (2006-11-01), pages 69, XP005810440, ISSN: 1359-6349 *
TAYLOR E M ET AL: "NEOTROFIN!TM PREVENTS VINCRISTINE - INDUCED PERIPHERAL NEUROPATHY IN THE RAT.", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, & 32ND ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; ORLANDO, FLORIDA, USA; NOVEMBER 02-07, 2002, pages Abstract No. 842.5 URL - http://sf, XP009093269 *

Also Published As

Publication number Publication date
KR20090047501A (en) 2009-05-12
WO2008017000A2 (en) 2008-02-07
RU2009107123A (en) 2010-09-10
CA2659477A1 (en) 2008-02-07
IL196824A0 (en) 2009-11-18
BRPI0715504A2 (en) 2014-05-06
EP2046335A2 (en) 2009-04-15
CN101657199A (en) 2010-02-24
WO2008017000A8 (en) 2009-04-30
JP2009545619A (en) 2009-12-24
MX2009001116A (en) 2009-02-10
ZA200900728B (en) 2010-03-31
NO20090279L (en) 2009-02-26

Similar Documents

Publication Publication Date Title
EP2450360A3 (en) (S)-N-Methylnaltrexone
WO2008052187A3 (en) Antibodies and immunoconjugates and uses therefor
AU2006272804A8 (en) Concentrated protein lyophilates, methods, and uses
WO2007140371A3 (en) Antibodies and immunoconjugates and uses therefor
WO2007121318A3 (en) Formulations for delivering insulin
WO2006131591A3 (en) An entacapone-containing oral dosage form
IL192967A0 (en) Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2008005705A3 (en) Metal-containing formulations and methods of use
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
TNSN08284A1 (en) Masking the taste of powders
WO2007130822A3 (en) Mglur5 modulators iii
WO2007144169A3 (en) Entacapone-derivatives
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
EP1831240B8 (en) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
WO2010100515A3 (en) Fractions of wheat germ ferment
WO2008110374A3 (en) Pellets containing a pharmaceutical substance, method for the production thereof and use of the same
WO2008019782A3 (en) Dispersions of nanoureas containing active ingredients
WO2008127382A3 (en) Computational design of ribozymes
CA120290S (en) Package for an ophthalmic product
WO2007075870A3 (en) Processes for taxane derivatives and intermediates useful therein
MX349563B (en) Pharmaceutical formulation of nanonised fenofibrate.
WO2007114946A3 (en) Acid-sensitive linkers for drug delivery
WO2008017000A3 (en) Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780028717.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07840646

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/001116

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009523049

Country of ref document: JP

Ref document number: 2659477

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 196824

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007840646

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097004261

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009107123

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0715504

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090129